Last updated: February 23, 2026
What is the Drug?
NDC 00527-2525 corresponds to Dextromethorphan HBr and Guaifenesin Syrup, marketed under various brand names, commonly used as a cough suppressant and expectorant. It is available over-the-counter (OTC), making its market dynamics less influenced by regulatory hurdles than prescription drugs.
Market Size and Demand Drivers
Customer Segments
- Consumer OTC Market: Primarily sold directly to consumers through pharmacies, retail outlets, and online platforms.
- Pharmacy & Retail Chains: Distributors of OTC cough and cold medications.
- Bulk & Institutional Use: Hospitals and clinics may purchase for inpatient use, though primarily less common for OTC formulations.
Key Demand Factors
- Seasonal flu and cold prevalence
- Public health campaigns encouraging cold remedies
- Consumer preference for combination cough medicines
- Increased online purchasing
Market Size
The global cough and cold remedy market was valued at approximately USD 13.2 billion in 2021, with OTC expectorants and cough suppressants representing roughly 40%. In the U.S. alone, sales of dextromethorphan-based products are around USD 1.5 billion annually.
Competitive Landscape
Major brands include Robitussin, Delsym, Mucinex, and private label store brands. These brands influence market share, with Dextromethorphan-based products holding ~60% of OTC cough medicine sales.
Regulatory Environment
- OTC Status: Recognized as safe for OTC sale with standard labeling, under the FDA monograph for cough suppressants and expectorants.
- Scheduling: Dextromethorphan is a Schedule V controlled substance in the U.S., with sales restrictions in certain states due to misuse concerns (e.g., recreational use among youth).
Price Trends and Projections
Historical Pricing (Retail)
| Year |
Average Retail Price (per 4 oz bottle) |
Notes |
| 2018 |
USD 8.50 |
Stable, with slight growth |
| 2019 |
USD 8.75 |
Slight increase |
| 2020 |
USD 9.00 |
Pandemic-induced variability |
| 2021 |
USD 9.25 |
Continued growth |
Factors Influencing Future Pricing
- Raw Material Costs: Guaifenesin and dextromethorphan prices have remained stable, with minor fluctuations tied to supply chain dynamics.
- Manufacturing Costs: Maintaining high-quality formulations influences pricing.
- Regulatory Changes: Stricter sales and monitoring could lead to limited supply, potentially increasing prices.
- Competitive Pressure: The proliferation of private-label options sustains price competition, limiting large increases.
Price Projections (Next 3-5 Years)
| Year |
Expected Retail Price (per 4 oz bottle) |
Assumptions |
| 2023 |
USD 9.50 |
Slight inflation, stable raw costs |
| 2024 |
USD 9.75 |
Regulatory impacts, supply stability |
| 2025 |
USD 10.00 |
Inflation, potential supply chain tightening |
Wholesale Pricing Estimates
Wholesale acquisition costs (WAC) approximate 40-50% of retail prices, currently around USD 4.25 - USD 4.75 per bottle. These prices are likely to increase proportionally with retail pricing and supply chain pressures.
Key Market Risks
- Changes in regulatory policies restricting sales, especially concerning dextromethorphan misuse.
- Increased competition from generic brands and private labels.
- Fluctuations in raw material costs or supply chain disruptions.
- Consumer shift toward natural or alternative remedies.
Strategic Opportunities
- Exploiting online and direct-to-consumer channels to expand market reach.
- Developing formulations with added benefits or reduced misuse potential.
- Partnering with pharmacy chains for exclusive distribution agreements.
Summary
The OTC dextromethorphan and guaifenesin syrup market remains sizable, with steady demand driven by seasonal illnesses. Prices are expected to grow modestly over the next five years, influenced by manufacturing costs, regulatory landscape, and market competition. Supply chain stability and regulatory compliance will be critical to maintaining profit margins and market share.
Key Takeaways
- The market for NDC 00527-2525 is approximately USD 1.5 billion annually in the U.S.
- Retail prices have increased roughly 2-3% annually over recent years.
- Future price growth is projected at 3-4% annually over the next five years, barring significant regulatory or supply chain disruptions.
- Competition from private labels and generics remains strong, constraining pricing power.
- Key regulatory developments regarding misuse potential may impact availability and pricing.
FAQs
1. What regulatory challenges might impact the market for this drug?
Regulatory concerns focus on misuse potential of dextromethorphan, leading to state-level restrictions and consumer education campaigns, which could influence sales and distribution channels.
2. How does consumer demand influence market pricing?
Consumer demand peaks during cold and flu seasons, which can temporarily raise prices. Long-term, demand stability supports steady price increases.
3. What is the typical markup from wholesale to retail?
The wholesale markup ranges from 40% to 50%, resulting in retail prices approximately 1.8 to 2.2 times the wholesale price.
4. Which competitors dominate the market, and how do they influence pricing?
Brand leaders include Robitussin, Delsym, and Mucinex, with significant private label competition. These brands keep prices competitive through volume and promotional strategies.
5. Are there any upcoming patent or formulation changes that could affect the market?
As an OTC, the formulation is generally stable under FDA monographs. Innovative formulations or new delivery methods would require regulatory approval, but none are currently announced.
References
- MarketWatch. (2022). Cough and cold remedy market size & forecast. Retrieved from https://www.marketwatch.com/
- U.S. Food and Drug Administration (FDA). (2022). Monograph for OTC cough medicines. Retrieved from https://www.fda.gov/
- Statista. (2022). OTC cough and cold medications—market statistics. Retrieved from https://www.statista.com/
- IMS Health. (2022). OTC market sales data. Retrieved from https://www.iqvia.com/
